Evidence map›Paper›PMID 41431198›Full record

ArticlePediatric hematology and oncology2026

Step-down management of fever and neutropenia in low-risk pediatric and adolescent-young adult oncology patients is safe and effective: a single center experience.

Priya H Marathe, Christine Camacho-Bydume, Charlie White, Audrey Mauguen, Michael Kinnaman, Kayleen A Bailey, Hannah Fassel, Mariel H Smith, Ashish C Massey, Susan K Seo and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric hematology and oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Priya H MaratheDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Christine Camacho-BydumeDepartment of Pediatric Hematology/Oncology, Joseph M. Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Charlie WhiteDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Audrey MauguenDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Michael KinnamanDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Kayleen A BaileyDivision of Pediatric Hematology-Oncology, Mount Sinai Kravis Children's Hospital, New York, NY, USA.
Hannah FasselHasbro Children's Hospital at Brown University Health, Providence, Rhode Island, USA.
Mariel H SmithHarvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, USA.
Ashish C MasseyDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Susan K SeoInfectious Disease Service, Dept of Medicine, Memorial Sloan Kettering Cancer Center, USA.
James S KillingerDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Leonard H WexlerDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Febrile neutropenia (FN) is a common complication in pediatric oncology patients that typically necessitates hospitalization for intravenous antibiotics, resulting in significant use of hospital resources and decreased patient and family quality of life. Recently several centers have published early discharge guidelines for patients with low-risk FN, but this has not yet been reported at large tertiary centers with high acuity. Here we describe implementation of a low-risk early discharge FN guideline at our tertiary cancer center with resulting decrease in median length of stay (2.39 days saved per early discharge encounter) and no adverse events, including sepsis or infection-related mortality.

Indexed as

Anti-Bacterial AgentsFebrile NeutropeniaFeverNeoplasmsNeutropeniaAdolescentAdultChildChild, PreschoolFemaleHumansMaleYoung AdultAnti-Bacterial Agentsearly hospital dischargeFebrile neutropenialow-risk algorithmout patient management

Identifiers

PMID41431198
PMCPMC13214593

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.